Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Eisai projects $7B in sales by 2030 for new Alzheimer's drug

Source: 
Endpoints
snippet: 

Eisai and Biogen’s newly approved Alzheimer’s drug Leqembi (lecanemab) is looking to do what its amyloid-targeted predecessor, Biogen’s Aduhelm (aducanumab), has yet to accomplish — hit blockbuster status.